

# Subclinical hypothyroidism and TSH screening

G. Michael Allan MD CCFP Michelle P. Morros MD CCFP Jennifer Young MD CCFP(EM)

## Clinical question

Is there evidence for screening for thyroid function or treating subclinical hypothyroidism?

## Bottom line

There are no RCTs of screening for thyroid function (ordering thyroid-stimulating hormone [TSH] testing in nonpregnant, healthy people). Despite approximately 20 RCTs, no patient-oriented benefits (like preventing cardiovascular disease or reduced fatigue or weight) have been identified from treating subclinical hypothyroidism. Guidelines recommend against both.

## Evidence

Screening for thyroid function:

- No RCTs or controlled observational studies assess screening for thyroid function or TSH tests for screening.<sup>1,2</sup> Treating subclinical hypothyroidism (TSH level of 4 to 10 mIU/L but normal triiodothyronine and thyroxine levels):
- Four systematic reviews from the past 5 years report on 18 to 21 RCTs.<sup>1-4</sup> Treatment of subclinical hypothyroidism (with levothyroxine, typically) versus placebo had no effect on mortality or new cardiovascular disease<sup>2-4</sup>; quality of life, depressive symptoms, fatigue, or thyroid-related symptoms scores<sup>1-4</sup>; cognitive function<sup>1-4</sup>; or body mass index or weight.<sup>1-4</sup>
- In the newest RCT (251 elderly patients, mean age 85 years), there was no benefit for any outcome (about 1.5 years' follow-up).<sup>5</sup>

## Context

- Subclinical hypothyroidism is generally defined as TSH levels of about 4 to 10 mIU/L, with normal triiodothyronine and thyroxine levels and no clear symptoms of hypothyroidism.
- Levels of TSH might vary up to 50% between tests,<sup>6</sup> and daily fluctuations<sup>7</sup> in individuals can be 26%.
- Prevalence of subclinical hypothyroidism (in the developed world) is 4% to 10%, with 2% to 6% of these developing overt hypothyroidism. Subclinical hyperthyroidism prevalence is about 2%, with 1% to 2% of these developing overt hyperthyroidism.<sup>2,8</sup>
  - Of those with subclinical hypothyroidism, 40% revert to normal TSH levels over about 2.5 years.<sup>9</sup>
  - Symptoms are often poor predictors (eg, one study found about 18% of euthyroid, 22% of subclinical hypothyroid, and 26% of overt hypothyroid patients reported  $\geq 4$  symptoms of hypothyroidism).<sup>10</sup>

- The Canadian Task Force on Preventive Health Care recommends against screening in asymptomatic, nonpregnant patients or treating subclinical hypothyroidism.<sup>11</sup>

## Implementation

Screening with TSH might be increasing, with 57% of 55-year-old women screened in one study.<sup>12</sup> However, screening thyroid tests resulted in less than 0.5% being treated for overt hypothyroidism.<sup>13</sup> The reason for screening asymptomatic patients with low-value tests like TSH is complicated but involves multiple factors including patient requests, physician practice patterns, and beliefs around screening. For patient requests, physicians should advise patients that the evidence available suggests screening TSH tests are very unlikely to be helpful (perhaps <1%), and if the result is only slightly abnormal (subclinical hypothyroidism), treating generally does not improve outcomes or symptoms. Additionally, prepopulated laboratory requisitions generally should not be used for screening asymptomatic patients, as screening will be individualized by person and visit.

**Dr Allan** is Director of Programs and Practice Support at the College of Family Physicians of Canada and Professor in the Department of Family Medicine at the University of Alberta in Edmonton.

**Dr Morros** is Assistant Professor in the Department of Family Medicine at the University of Alberta. **Dr Young** is a family physician practising in Collingwood, Ont.

**Competing interests**  
None declared

**The opinions expressed** in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

## References

1. Ruggie JB, Bougatsos C, Chou R. Screening and treatment of thyroid dysfunction: an evidence review for the US Preventive Services Task Force. *Ann Intern Med* 2015;162(1):35-45.
2. Reyes Domingo F, Avey MT, Doull M. Screening for thyroid dysfunction and treatment of screen-detected thyroid dysfunction in asymptomatic, community-dwelling adults: a systematic review. *Syst Rev* 2019;8(1):260.
3. Bekkering GE, Agoritsas T, Lytlyn L, Heen AF, Feller M, Moutzouri E, et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. *BMJ* 2019;365:l2006.
4. Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D, et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. *JAMA* 2018;320(13):1349-59.
5. Mooijjaart SP, Du Puy RS, Stott DJ, Kearney PM, Rodondi N, Westendorp RGJ, et al. Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism. *JAMA* 2019 Oct 30. Epub ahead of print.
6. McCormack J, Holmes DT. Your results may vary: a precise discussion about the imprecision of medical measurements. *BMJ*. In press.
7. Scobbo RR, VonDohlen TW, Hassan M, Islam S. Serum TSH variability in normal individuals: the influence of time of sample collection. *W V Med J* 2004;100(4):138-42.
8. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. *J Clin Endocrinol Metab* 2005;90(1):581-5.
9. Diez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. *J Clin Endocrinol Metab* 2004;89:4890-7.
10. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. *Arch Intern Med* 2000;160(4):526-34.
11. Birtwhistle R, Morissette K, Dickinson JA, Reynolds DL, Avey MT, Domingo FR, et al. Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care. *CMAJ* 2019;191(46):E1274-80.
12. Chacko KM, Feinberg LE. Laboratory screening at preventive health exams: trend of testing, 1978-2004. *Am J Prev Med* 2007;32(1):59-62.
13. Boland BJ, Wollan PC, Silverstein MD. Yield of laboratory tests for case-finding in the ambulatory general medical examination. *Am J Med* 1996;101(2):142-52.

This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to [www.cfp.ca](http://www.cfp.ca) and click on the Mainpro+ link.

Cet article se trouve aussi en français à la page 189.

**Tools for Practice** articles in *Canadian Family Physician* are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in *Canadian Family Physician* are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to [toolsforpractice@cfpc.ca](mailto:toolsforpractice@cfpc.ca). Archived articles are available on the ACFP website: [www.acfp.ca](http://www.acfp.ca).